Clinical Trial Update: Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients [Phase 3]

View source ↗

Summary

This Phase 3 extension study evaluated the safety and efficacy of Aldurazyme (laronidase) in patients with Mucopolysaccharidosis I and has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hurler Syndrome
• Hurler-scheie Syndrome
• Mucopolysaccharidosis Type
• Scheie Syndrome

Drugs mentioned

• Aldurazyme (Laronidase)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Mucopolysaccharidosis I, Hurler's Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2009-06-16